Spots Global Cancer Trial Database for ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
Official Title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan in Patients With Previously Treated,Incurable Ewing Sarcoma
Study ID: NCT02044120
Conditions
Study Description
Brief Summary: The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 13 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Children's Hospital of Los Angeles, Los Angeles, California, United States
National Cancer Institute, Bethesda, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
Seattle's Children Cancer Center, Seattle, Washington, United States
University College London Hospital, London, , United Kingdom
Contact Details
Name: Rashmi Chugh, MD
Affiliation: University of Michigan
Role: PRINCIPAL_INVESTIGATOR
Name: Sandra Strauss, MBBS, PhD
Affiliation: University College London, Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
